AstraZeneca, Lilly, Novo Look To China Growth Despite Pricing Headwinds – Emerging Market Earnings Roundup (Part 1)
This article was originally published in PharmAsia News
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.
You may also be interested in...
With the longtime CEO stepping down as of June 1, his successor will assume the challenge of handling generic challengers to several mature blockbuster products and the slow launch of Brilinta. The current business-development strategy, as reflected in a recent partnership and acquisition, is expected to stay in place for now.
AstraZeneca’s Nexium, GSK’s Zofran Among Latest Victims Of China Price Cuts; NDRC Plans Further Pricing Reforms To Encourage Innovation
China has announced another round of price cuts, this time targeting digestive drugs, which will impact AstraZeneca, GlaxoSmithKline and other MNCs.
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country